methylprednisolone has been researched along with busulfan in 39 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.13) | 18.7374 |
| 1990's | 9 (23.08) | 18.2507 |
| 2000's | 18 (46.15) | 29.6817 |
| 2010's | 9 (23.08) | 24.3611 |
| 2020's | 1 (2.56) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Essell, JH; Halvorson, RD; Harman, GS; Johnson, RA; Rubinsak, JR; Snyder, MJ; Thompson, JM | 1 |
| Bell, JB; Gore, ME; Maitland, JA; McElwain, TJ; Millar, BC; Selby, PJ; Zuiable, A | 1 |
| Baxter-Lowe, LA; Bunin, N; Camitta, B; Casper, J; Garbrecht, F; Hunter, J; Lawton, C; Murray, K; Pietryga, D; Truitt, R | 1 |
| Anasetti, C; Anderson, JE; Appelbaum, FR; Bensinger, WI; Bryant, E; Buckner, CD; Chauncey, T; Clift, RA; Gooley, T; Schoch, G | 1 |
| Grande, M | 1 |
| Akan, H; Arslan, O; Beksaç, M; Gürman, G; Ilhan, O; Koç, H; Konuk, N; Ozcan, M; Uysal, A; Yalçín, S | 1 |
| Bertz, H; Finke, J; Mertelsmann, R; Potthoff, K | 1 |
| Kato, K; Kojima, S; Matsuyama, T | 1 |
| Kato, K; Kojima, S; Kondo, M; Matsuyama, T | 1 |
| Berger, C; Braumann, D; de Witt, M; Erttmann, R; Fiedler, W; Grimm, J; Horstmann, M; Hossfeld, KD; Illiger, HJ; Kabisch, H; Kröger, N; Krüger, W; Kuse, R; Schönrock, P; Stockshläder, M; Weh, HJ; Zander, AR; Zeller, W | 1 |
| Bhagwati, N; Horton, C; Kulkarni, S; Mainwaring, P; Mehta, J; Pandha, H; Powles, R; Singhal, S; Sirohi, B; Treleaven, J | 1 |
| Atkinson, R; Forman, S; Kashyap, A; Lund, BT; Openshaw, H; Sniecinski, I; Weiner, LP | 1 |
| Fujioka, T; Hirabayashi, N; Ikegame, K; Kawakami, M; Murakami, M; Ogawa, H; Soma, T; Sugiyama, H; Takahashi, R; Takimoto, T; Tamaki, H | 1 |
| Chi, HS; Kim, WK; Lee, JH; Lee, JS; Lee, KH | 1 |
| Arcese, W; Cerretti, R; De Felice, L; Donato, V; Fenu, S; Guglielmi, C; Iori, A; Laurenti, L; Mengarelli, A; Micozzi, A; Romano, A; Torromeo, C | 1 |
| Fukiya, E; Kimura, S; Kobayashi, Y; Kuroda, J; Murotani, Y; Ozawa, M; Terao, K; Yoshikawa, T | 1 |
| Albert, MH; Enders, A; Haas, RJ; Muntau, AC; Peters, C; Pontz, BF; Röschinger, W; Schmid, I; Schulze, S; Schuster, F; Stachel, DK | 1 |
| ENGLE, RL; KAUER, GL | 1 |
| Kobayashi, K; Kobayashi, R; Mino, E; Suzuki, Y; Yamada, M; Yoshida, M | 1 |
| Diaconescu, R; Maloney, DG; Maris, MB; McSweeney, P; Parikh, CR; Sandmaier, BM; Schrier, RW; Sorror, ML; Storb, R; Storer, B | 1 |
| Chen, C; Chen, W; Fang, JP; Feng, HY; Feng, SW; Huang, K; Huang, SL; Li, Y; Li, Z; Liu, Y; Lu, XL; Wen, JM; Xi, J; Xiao, LL; Xie, YM; Xu, HG; Yao, XL; Ye, X; Zeng, Y; Zhang, C; Zhang, M; Zhang, WX; Zhou, DH | 1 |
| Fujioka, T; Hasei, H; Ikegame, K; Inoue, T; Kaida, K; Kawakami, M; Kawase, I; Kim, EH; Masuda, T; Ogawa, H; Taniguchi, Y; Yoshihara, S | 1 |
| Acebo, E; Díaz-Pérez, JL; García-Ruiz, JC; Izu, R; Martínez de Lagrán, Z; Pérez-Barrio, S | 1 |
| Chen, ZC; Li, L; Li, QB; Xia, LH; You, Y; Zou, P | 1 |
| Adorno, G; Alfieri, C; Andreani, M; Daniele, N; De Angelis, G; Del Proposto, G; Gallucci, C; Gaziev, J; Isgrò, A; Lanti, A; Lucarelli, G; Marziali, M; Paciaroni, K; Roveda, A; Saltarelli, F; Simone, MD; Sodani, P; Testi, M | 1 |
| Choquet, S; del Rio, MS; Fourme, E; Glaisner, S; Hoang-Xuan, K; Janvier, M; Soussain, C | 1 |
| Angelopoulou, MK; Beris, P; Constantinou, N; Dervenoulas, J; Diamantopoulos, P; Dimopoulos, MA; Dimou, M; Economopoulou, C; Economopoulou, P; Efthimiou, A; Georgiou, G; Kalpadakis, C; Katsigiannis, A; Korkolopoulou, P; Kotsianidis, I; Kyrtsonis, MC; Levidou, G; Meletis, J; Panayiotidis, P; Pangalis, GA; Papageorgiou, SG; Pappa, V; Tsirigotis, P; Vassilakopoulos, TP | 1 |
| Abdel-Azim, H; Crooks, GM; Kapoor, N; Khazal, S; Kohn, DB; Mahadeo, KM; Shah, AJ; Zhao, Q | 1 |
| Dandoy, CE; Davies, SM; El-Bietar, J; Grimley, MS; Khandelwal, P; Lane, A; Yeh, RF; Yu, L | 1 |
1 review(s) available for methylprednisolone and busulfan
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
7 trial(s) available for methylprednisolone and busulfan
| Article | Year |
|---|---|
Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide.
Topics: Actuarial Analysis; Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Female; Follow-Up Studies; Graft vs Host Disease; Hepatic Veno-Occlusive Disease; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Methotrexate; Methylprednisolone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Time Factors; Whole-Body Irradiation | 1992 |
Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors.
Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Graft vs Host Disease; Humans; Immunosuppression Therapy; Infections; Karyotyping; Methotrexate; Methylprednisolone; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recurrence; Regression Analysis; Survival Rate; Treatment Outcome; Whole-Body Irradiation | 1996 |
High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia, Myeloid; Male; Methotrexate; Methylprednisolone; Middle Aged; Remission Induction; Time Factors; Transplantation, Homologous | 1997 |
The role of autologous transplantation in patients with multiple myeloma aged 65 years and over.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Chemical and Drug Induced Liver Injury; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Graft Survival; Heart Diseases; Hematopoietic Stem Cell Mobilization; Hospitalization; Humans; Interferons; Kidney Diseases; Male; Matched-Pair Analysis; Melphalan; Methylprednisolone; Middle Aged; Multiple Myeloma; Neutropenia; Neutrophils; Platelet Count; Recurrence; Sepsis; Survival Rate; Thrombocytopenia; Transplantation, Autologous; Vincristine | 2000 |
Non-myeloablative conditioning regimen of fludarabine, busulfan, anti-thymocyte globulin, and methylprednisolone for allogeneic peripheral blood hematopoietic cell transplantation.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Methylprednisolone; Middle Aged; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2001 |
Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
Topics: Adult; Antilymphocyte Serum; Bone Marrow; Busulfan; CD4 Lymphocyte Count; Combined Modality Therapy; Cytokines; Disease-Free Survival; Family; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility; HLA Antigens; Humans; Immunosuppressive Agents; Incidence; Male; Methylprednisolone; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; T-Lymphocytes; Tacrolimus; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2006 |
Higher CD3(+) and CD34(+) cell doses in the graft increase the incidence of acute GVHD in children receiving BMT for thalassemia.
Topics: Acute Disease; Adolescent; Anti-Inflammatory Agents; Antigens, CD34; Bone Marrow Transplantation; Busulfan; CD3 Complex; Child; Child, Preschool; Cyclophosphamide; Female; Graft vs Host Disease; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Incidence; Infant; Male; Methotrexate; Methylprednisolone; Myeloablative Agonists; Siblings; Thalassemia; Transplantation Conditioning; Transplantation, Homologous | 2012 |
31 other study(ies) available for methylprednisolone and busulfan
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
In vitro studies of ways to overcome resistance to VAMP--high dose melphalan in the treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cell Survival; Colony-Forming Units Assay; Daunorubicin; Doxorubicin; Drug Resistance; Humans; Melphalan; Methylprednisolone; Multiple Myeloma; Tumor Cells, Cultured; Tumor Stem Cell Assay; Verapamil; Vincristine | 1989 |
Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia.
Topics: Actuarial Analysis; Adolescent; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Hepatic Veno-Occlusive Disease; Histocompatibility; Humans; Infections; Leukemia; Lung Diseases, Interstitial; Male; Methylprednisolone; Myelodysplastic Syndromes; Retrospective Studies; Risk Factors; Survival Analysis; Tissue Donors; Treatment Outcome; Whole-Body Irradiation; Wisconsin | 1995 |
Central nervous system granulocytic sarcoma in a patient with essential thrombocythemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blast Crisis; Bone Marrow; Busulfan; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease Progression; Epidural Space; Fatal Outcome; Frontal Bone; Humans; Leukemia, Myeloid; Leukemic Infiltration; Male; Methylprednisolone; Spinal Canal; Thrombocythemia, Essential | 1996 |
Eosinophilia after allogeneic bone marrow transplantation using busulfan and cyclophosphamide conditioning regimen.
Topics: Bone Marrow Transplantation; Busulfan; Chronic Disease; Cyclophosphamide; Eosinophilia; Graft vs Host Disease; Humans; Immunosuppressive Agents; Incidence; Leukemia; Methylprednisolone; Transplantation Conditioning; Transplantation, Homologous | 1996 |
Busulfan/cyclophosphamide in volunteer unrelated donor (VUD) BMT: excellent feasibility and low incidence of treatment-related toxicity.
Topics: Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cyclosporine; Female; Graft Survival; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia; Living Donors; Male; Methotrexate; Methylprednisolone; Middle Aged; Myelodysplastic Syndromes; T-Lymphocytes; Transplantation Conditioning | 1997 |
Allogeneic bone marrow transplantation for childhood leukemia following a busulfan and melphalan preparative regimen.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Female; Glucocorticoids; Graft vs Host Disease; Growth; Humans; Infant; Leukemia, Myeloid, Acute; Male; Melphalan; Methylprednisolone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Homologous | 1998 |
Late-onset hemorrhagic cystitis after hematopoietic stem cell transplantation in children.
Topics: Adolescent; Age Factors; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cyclosporine; Cystitis; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hematuria; Humans; Immunosuppressive Agents; Incidence; Infant; Infant, Newborn; Japan; Leukemia; Male; Methylprednisolone; Risk Factors | 1998 |
Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring.
Topics: Adult; Autoantibodies; Autoantigens; Autoimmune Diseases; Brain; Busulfan; Cells, Cultured; Combined Modality Therapy; Cyclophosphamide; Cytotoxicity, Immunologic; Disease Progression; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunodominant Epitopes; Immunosuppression Therapy; Immunosuppressive Agents; Infections; Lymphocyte Activation; Magnetic Resonance Imaging; Methylprednisolone; Middle Aged; Multiple Sclerosis; Myelin Sheath; T-Lymphocyte Subsets; Transplantation Conditioning; Treatment Outcome | 2000 |
Lethal adenovirus infection in a patient who had undergone nonmyeloablative stem cell transplantation.
Topics: Adenoviridae Infections; Adenoviruses, Human; Antilymphocyte Serum; Bronchoalveolar Lavage Fluid; Busulfan; Cystitis; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppressive Agents; Leukemia, Myeloid, Chronic-Phase; Lymphocyte Count; Lymphocyte Subsets; Male; Methylprednisolone; Middle Aged; Pneumonia, Viral; T-Lymphocytes; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |
Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Cytarabine; Disease-Free Survival; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Infant; Leukemia; Life Tables; Male; Methylprednisolone; Middle Aged; Premedication; Retrospective Studies; Risk; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2002 |
Non-myeloablative haematopoietic stem cell transplantation for severe aplastic anaemia with various complications.
Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Busulfan; Female; Fractures, Bone; Graft Rejection; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Intellectual Disability; Male; Methylprednisolone; Mycophenolic Acid; Obesity; Peripheral Blood Stem Cell Transplantation; Prednisolone; Remission Induction; Siblings; T-Lymphocytes; Tacrolimus; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Vidarabine | 2002 |
T-cell-depleted peripheral blood stem cell transplantation for alpha-mannosidosis.
Topics: alpha-Mannosidosis; Anti-Inflammatory Agents; Antigens, CD34; Bone and Bones; Busulfan; Cyclophosphamide; Female; Humans; Immunophenotyping; Immunosuppressive Agents; Infant; Lymphocyte Depletion; Male; Methylprednisolone; Muromonab-CD3; Oligosaccharides; Peripheral Blood Stem Cell Transplantation; Phenotype; T-Lymphocytes; Time Factors | 2003 |
EOSINOPHILIC LEUKAEMIA WITH PH1-POSITIVE CELLS.
Topics: Busulfan; Chromosome Aberrations; Chromosome Disorders; Eosinophilia; Humans; Hypereosinophilic Syndrome; Leukemia; Leukemia, Myeloid; Mercaptopurine; Methylprednisolone; Prednisone | 1964 |
Umbilical cord blood stem cell transplantation from unrelated HLA-matched donor in an infant with severe congenital neutropenia.
Topics: Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cyclosporine; DNA Fingerprinting; DNA Mutational Analysis; Granulocyte Colony-Stimulating Factor; Histocompatibility Testing; HLA Antigens; Humans; Infant; Male; Methylprednisolone; Neutropenia; Neutrophils; Recombinant Proteins; Respiratory Tract Infections; Time Factors; Tissue Donors; Tomography, X-Ray Computed; Transplantation Conditioning; Transplantation, Homologous | 2004 |
Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Busulfan; Cohort Studies; Comorbidity; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Incidence; Male; Methotrexate; Methylprednisolone; Middle Aged; Mycophenolic Acid; Patient Selection; Postoperative Complications; Recurrence; Renal Dialysis; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2005 |
[Therapy of Duchenne muscular dystrophy with umbilical cord blood stem cell transplantation].
Topics: Alprostadil; Busulfan; Child; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclosporine; Dystrophin; Ganciclovir; Humans; Male; Methylprednisolone; Muscular Dystrophy, Duchenne; Polymerase Chain Reaction; Treatment Outcome | 2005 |
[Autologous hematopoietic stem cell transplantation followed by oral bexarotene in a patient with advanced mycosis fungoides].
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Busulfan; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Interferon alpha-2; Interferon-alpha; Mechlorethamine; Methylprednisolone; Mycosis Fungoides; Peripheral Blood Stem Cell Transplantation; Prednisone; PUVA Therapy; Recombinant Proteins; Remission Induction; Tetrahydronaphthalenes; Transplantation, Autologous; Vincristine | 2008 |
A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Aspergillus; Busulfan; China; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Idarubicin; Immunosuppressive Agents; Leukemia; Leukemia, Myeloid, Acute; Male; Methylprednisolone; Mucositis; Pneumonia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Premedication; Retrospective Studies; Risk Factors; Semustine; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2009 |
Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Cisplatin; Cytarabine; Dexamethasone; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma; Male; Methylprednisolone; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Rituximab; Salvage Therapy; Thiotepa; Young Adult | 2011 |
Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Carmustine; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Humans; Incidence; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Male; Mediastinal Neoplasms; Methotrexate; Methylprednisolone; Middle Aged; Prednisone; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rituximab; Salvage Therapy; Stem Cell Transplantation; Thiotepa; Vincristine; Young Adult | 2013 |
Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal, Humanized; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Drug Administration Schedule; Female; Gene Expression; Genetic Diseases, Inborn; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Immunosuppressive Agents; Infant; Male; Methylprednisolone; Myeloablative Agonists; Pilot Projects; Survival Analysis; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine | 2015 |
Graft-versus-host Disease Prophylaxis With Abatacept Reduces Severe Acute Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant for Beta-thalassemia Major With Busulfan, Fludarabine, and Thiotepa.
Topics: Abatacept; Adolescent; beta-Thalassemia; Busulfan; Calcineurin Inhibitors; Child; Child, Preschool; Drug Administration Schedule; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Methylprednisolone; Retrospective Studies; Thiotepa; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2021 |